Organogenesis’ Q2 Operating Income Fell 50%, Lowers Annual Guidance
Organogenesis Holdings Inc’s (NASDAQ:ORGO) Q2 FY22 sales reached $121.4 million, down 1% Y/Y, slightly ahead of the consensus of $120.90…
Aridis’ Inhaled Pan-Coronavirus Antibody Cocktail Shows Encouraging Preclinical Action
Aridis Pharmaceuticals Inc’s (NASDAQ:ARDS) inhaled treatment of its fully human monoclonal antibody cocktail AR-701 resulted in no detectable SARS-CoV-2 virus in…
VYNE Therapeutics Shares Disappointing Data From Atopic Dermatitis Trial
VYNE Therapeutics Inc (NASDAQ: VYNE) has announced results from the Phase 2a segment of Phase 1b/2a trial evaluating FMX114 for mild-to-moderate atopic dermatitis.
Aridis Says Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective In Non-Human Primates
Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that inhaled
Volition Announces U.S. Clinical Study For Neutrophil Extracellular Traps
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of
To Avoid Supply Crunch, FDA Temporarily Allows Higher Impurity Levels In Merck’s Diabetes Drug: Report
The FDA recently became aware of a nitrosamine impurity, Nitroso-STG-19 or NTTP, in certain samples of Merck & Co Inc's (NYSE: MRK) type 2 diabetes drug Januvia/Janumet (sitagliptin).
Recap of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset…
Olema Oncology Advances OP-1250 Into Phase 2 Monotherapy Expansion In Patients With ER+/HER2- Advanced Breast Cancer
SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), today announced the advancement of OP-1250, a complete estrogen receptor
Analysts See Softened Timelines For CRISPR Therapeutics’ Sickle Cell Candidate In US
Barclays says that CRISPR Therapeutics AG’s (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the…
Amneal Pharmaceuticals Granted FDA Orange Book Approval For VASOPRESSIN
https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=212944#181